Mrs Azizah Attard

Advanced Highly Specialist Mental Health Pharmacist

Mrs Azizah Attard

Mrs Azizah Attard is a highly advanced specialist mental health pharmacist who provides expert evidence in cases involving psychotropic medication.

Instructing Mrs Azizah Attard

If you want to instruct Mrs Attard or if you want to discuss using Mrs Attard for your case, please contact us.

Contact us

Profile

Azizah has been a practicing specialist mental health pharmacist for over 20 years. Holding very senior management positions within secondary and tertiary care, she specialises in providing evidence-based medicines information. Azizah has extensive experience working at a national level, having sat on the expert panel of both the National Psychosis Unit and National Affective Disorder Unit. She has a proven track record for establishing and developing new services and driving quality improvement within large healthcare organisations. Azizah has led large pharmacy teams in secondary mental health services. She also regularly provides assessment and treatment intervention for patients across the UK, in primary care settings. Routinely advising on the potential for a medication related side effect, the best evidence based choice in therapy (antipsychotics, antidepressants and mood stabilisers) as well as commenting on the use of therapies in treatment resistant schizophrenia and depression are areas in which Azizah excels. Often a highly experienced pharmacists’ clinical opinion can be uniquely evidence based, individualised to a patient’s case and can incorporate lesser known treatments, outside national guidance.

Experience of giving evidence

Azizah has given evidence at tribunal hearings, as part of serious untoward incident investigations and has provided expert opinion to inform both national and international guidelines on the use of psychotropic medication.

Cases undertaken

Azizah is most commonly instructed in the following types of cases:

  • Pharmaceutical negligence
  • Fitness to Practice
  • Pharmaceutical services
  • Expert advice on psychopharmacological treatment options (for example in the case of detained patients who have been unable to progress as a result of their symptoms of mental disorder)
  • Advice on the likelihood of a medication related side effect or adverse effect is associated with a change in behaviour, presentation and improvement or worsening of behaviour.
  • If the treatment offered at the time of an offence or to date is in line with national guidance or evidence base.
  • A drug history spanning the individuals care with services; this will include any possible side effects and clinical effectiveness or ineffectiveness of the treatment. Whether the treatment offered was at a therapeutic level and time line.

Specialist assessments offered

  • Pharmaceutical negligence
  • Fitness to Practice
  • Pharmaceutical services
  • Expert advice on psychopharmacological treatment options (for example in the case of detained patients who have been unable to progress as a result of their symptoms of mental disorder)
  • Advice on the likelihood of a medication related side effect or adverse effect is associated with a change in behaviour, presentation and improvement or worsening of behaviour.
  • If the treatment offered at the time of an offence or to date is in line with national guidance or evidence base.
  • A drug history spanning the individuals care with services; this will include any possible side effects and clinical effectiveness or ineffectiveness of the treatment. Whether the treatment offered was at a therapeutic level and time line.

Publications

 In review at Therapeutic Advances in Psychopharmacology : Treating Psychiatric Conditions of patients with Co-morbid Postural Orthostatic Tachycardia Syndrome  (POTS). Attard A, Stanniland C, Rajappan K, Iles A, Attard S. Jan 2022

In review at Therapeutic Advances in Psychopharmacology Olanzapine Long Acting Injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK High Secure Hospital  Attard A*, Wakelam J, Broyd J, Taylor D, Hafferty J

Brugada Syndrome; should we be actively screening patients for this before prescribing a psychotropic medication? Attard A, Stanniland C, Rajappan K, Iles A, Attard S. Therapeutic Advances in Psychopharmacology: Oct 2021

My career as a mental health pharmacist during covid 19. Chopra P, Attard A and Parekh R. Pharmacy Management. May 2021

Clozapine: Why wait to start a laxative? Attard A, Iles A, Attard S, A Patel, N Atkinson. British Journal in Psychiatry Advances. May 2019

Paliperidone palmitate long-acting injection – prospective year-long follow-up of use  in clinical practice. Attard A, Olofinjana O, Cornelius V, Curtis V, Taylor D. Acta Psychiatr Scand. 2014 Jul;130(1):46-51. Epub 2013 Oct 1.

Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study. Samuel R, Attard A, Kyriakopoulos M. BMC Psychiatry. 2013 Oct 4;13:244.

Antidepressants. Medicine 40(12); 681-183. December 2012, Azizah Attard

Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? Attard A, Taylor DM. CNS Drugs. 2012 Jun 1;26(6):491-508.Review.

Acetylcholinesterase Inhibitors (AChEI’s) for the treatment of visual hallucinations in schizophrenia: a review of the literature. Patel SS, Attard A, Jacobsen P, Shergill S. BMC Psychiatry. 2010 Sep 7;10:69. Review.

Review: limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia. Attard A, Gaughran F. Evid Based Ment Health. 2009 Nov;12(4):112

Alternative routes to oral antidepressant therapy: case vignette and literature review. Attard A, Ranjith G, Taylor D. J Psychopharmacol. 2010 Apr;24(4):449-54. Review.

Delirium and its treatment. Attard A, Ranjith G, Taylor D. CNS Drugs. 2008;22(8):631-44. Review.

A career as a psychiatric liaison pharmacist. Pharmaceutical Journal. 2008: 15(3). A Attard ; D McRobbie ; DM Taylor ; T West

Contributions to other publications

Service Improvement Guide: Self Administration of Medicines in Mental Health Hospitals

National Prescribing Centre 2008

Maudsley Prescribing Guidelines, South London and Maudsley and Oxleas NHS Trusts

Poster publications

Treating Psychiatric Conditions of patients with Co-morbid Postural Orthostatic Tachycardia Syndrome  (POTS). Attard A, Iles A, Attard S

British Association of Psychopharmacology 2021 Summer Meeting
Brugada Syndrome; should we be actively screening patients for this before prescribing a psychotropic medication?
Attard A, Iles A, Attard S

Clinical Pharmacy Congress 2021
The impact one pharmacist can have on Medicines Optimisation at Crisis Teams in 3 large London Boroughs
Nichofuric A and Attard A

Clinical Pharmacy Congress 2020
The impact a Prescribing Pharmacist had on a Community Mental Health Team
Stanniland C and Attard A

To measure the impact of digital temperature monitoring in clinical areas of a large London NHS Trust
Faculty of Clinical Informatics and Annual Scientific Conference 2020
Mouzaki S, Attard A and Monaharan G

International Congress 2015 Psychiatry, Birmingham 29 June-2 July 2015
Clozapine – does the GP know what the hospital is doing?
E Hardwood, A Attard, F Gaughran.

17th Bienniel Winter Workshop on Schizophrenia, Marrakech, 14-16 February 2013
A naturalistic evaluation of the use of paliperidone palmitate at a South London NHS Foundation Trust: Factors that predict continuation with treatment in 216 patients
A Attard, DM Taylor

A naturalistic evaluation of the use of paliperidone palmitate at South London and Maudsley NHS Foundation Trust: Interim results on bed stay and admission rates on the first 132 patients diagnosed with Schizophrenia who were followed up for 12 months.
A Attard, DM Taylor

British Association of Psychopharmacology 2012 Summer Meeting
A naturalistic evaluation of the use of paliperidone palmitate at a South London TF07 NHS Foundation Trust: 6 month interim results on the first 120 patients
Attard, A., Taylor, DM.

Keynote speaker presentations

A naturalistic evaluation of the use of paliperidone palmitate (PP) at South London and Maudsley NHS Foundation Trust: The same old story? A Attard for Prof D M Taylor

Conference oral presentations

17th Bienniel Winter Workshop on Schizophrenia, Marrakech, 14-16 February 2013
Expert Panel Member on Treatment Resistant Schizophrenia With the National Psychosis Unit

Schizophrenia Research In Science (SIRS), Florence 2012
“Cardiovascular side effects of antipsychotics”

National Psychosis Unit training days at locations across the United Kingdom for the Royal College of Psychiatrists
“Medication Options in Treatment Resistant Schizophrenia”

Availability

Azizah is available on Wednesdays and Fridays for assessments.

Qualifications and memberships

Qualifications

2020 Education Programme Director and Supervisor Course

2012 Independent Prescribing Skills Course Summer KCL

2006 Supplementary Prescribing Skills Course

2006 Continuing Professional Development Coordinator Course LPET

2005 Ethics in Medical Research Course KCL

2004 Postgraduate Diploma in General Pharmacy Practice (DipGPP)

1995 BPharm Otago University

Memberships  

2001 Member of General Pharmaceutical Council UK

2001 Member of Royal Pharmaceutical Society UK

2000 Member of Australian Pharmaceutical Council

1999 Member of New Zealand Pharmaceutical Council

1999 Psychopharmacology Postgraduate Certificate Otago University

You can request to view the CV of any of our experts or contact us to discuss your requirements.